Noonan syndrome arises from differences in the way certain cellular signaling pathways function during development, and the genetic basis of the condition is heterogeneous, with multiple recognized subtypes described in the medical literature. Because of this heterogeneity, the responsible genetic change is not always identified through initial testing, and a comprehensive genetic evaluation is often necessary. Inheritance patterns differ by subtype, and many individuals are the first in their family to be affected, while others have a family history consistent with transmission from one generation to the next. Genetic counseling is an important component of evaluation and helps families understand the implications of a confirmed or suspected diagnosis, the likelihood of recurrence in future pregnancies, and options for relatives who may wish to be evaluated.

Diagnosis of Noonan syndrome typically begins with a clinical evaluation by a physician familiar with genetic conditions, who reviews the individual's medical history, growth pattern, and physical features. Genetic testing plays a central role in confirming the diagnosis and distinguishing the specific subtype, and testing strategies often involve multigene panels designed to evaluate several genes associated with Noonan syndrome and related conditions simultaneously. Because the condition can be suspected before birth in some cases, prenatal evaluation may include detailed ultrasound and, in some circumstances, prenatal genetic testing performed in consultation with a genetics specialist. After an initial diagnosis, evaluations commonly include a cardiac assessment with echocardiogram and electrocardiogram, growth and developmental assessments, hearing and vision evaluation, and screening for bleeding or coagulation differences. Symptoms of Noonan syndrome can overlap with other conditions, and genetic testing is required to confirm the diagnosis and distinguish it from conditions with similar presentations.

There is no single therapy that addresses all aspects of Noonan syndrome, and management is individualized and coordinated across multiple specialties. Care typically involves a team that may include cardiology, endocrinology, hematology, developmental specialists, and primary care, with additional input from other specialists as clinical needs arise. Cardiac findings are managed according to the specific abnormality identified, and ongoing cardiology follow-up is an important part of long-term care. Growth concerns are evaluated by endocrinology, and individualized treatment decisions are made in consultation with specialists familiar with growth in genetic conditions. Bleeding concerns are evaluated by hematology when relevant, and individuals may receive guidance regarding precautions before surgical or dental procedures. Developmental and educational support is provided through early intervention services, school-based programs, and therapies such as speech, occupational, or physical therapy as appropriate. Regular surveillance is an essential part of long-term care, helping to identify potential complications before they become serious. Investigational treatments targeting the underlying signaling pathway are under study, and a designated investigational therapy has been identified for evaluation in the management of cardiomyopathy associated with Noonan syndrome. Patients should discuss treatment options with their healthcare team to determine which therapies may be appropriate for their specific situation.

The long-term outlook for individuals with Noonan syndrome varies and depends on the specific combination of features present, the severity of cardiac involvement, and the quality and consistency of medical follow-up. Many individuals lead full and active lives with appropriate medical care, educational support, and surveillance for known complications. Cardiac findings, particularly hypertrophic cardiomyopathy and significant pulmonary valve abnormalities, are an important determinant of long-term outcomes, and ongoing cardiology follow-up is therefore an important component of care. With current standards of care, growth and developmental concerns can often be addressed through coordinated medical and educational services. Bleeding tendencies, when present, are generally manageable with awareness and appropriate planning around procedures. Outcomes have improved with earlier diagnosis, multidisciplinary care, and increasing recognition of the condition by primary care and specialty providers.

Numerous clinical studies are currently underway in Noonan syndrome and related conditions, reflecting active research interest in the condition. Ongoing studies include a Phase 3 trial sponsored by Novo Nordisk comparing investigational and established growth treatment regimens in children with growth-related conditions, and a Phase 3 trial sponsored by Ascendis Pharma evaluating a weekly growth therapy compared to a daily regimen in individuals with short stature. A Phase 2 basket study sponsored by BioMarin Pharmaceutical is evaluating vosoritide in individuals with Noonan syndrome and related conditions who have inadequate growth response to prior treatment. Additional studies hosted at academic and government centers are examining the underlying biology of Noonan syndrome and related RASopathies, including a clinical and epidemiologic study sponsored by the National Cancer Institute and a biological collection study at the University Hospital of Toulouse. Individuals interested in clinical trials can search ClinicalTrials.gov or consult their care team about eligibility.